CombiGene AB (publ) (COMBI.ST)

3.1000 +0.1200 (+4.03%) 收市：05:20PM CEST

CombiGene AB (publ)

Agavagen 52A
Lidingö 181 55
Sweden
46 8 35 73 55
https://www.combigene.com

版塊: Healthcare
行業: Biotechnology
全職員工: 10

描述

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.

公司管治

截至 無 止，CombiGene AB (publ) 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。